Blackstone, a private equity firm, agreed to invest $430m in Amicus Therapeutics, a biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases. “This new financing with Blackstone strengthens our balance sheet and financial profile by reducing the interest rate versus our current debt, pushing out the amortization schedule and extending the amortization period. This strategic investment demonstrates Blackstone’s commitment to Amicus’ future and belief in the strong growth potential of Galafold and Pombiliti + Opfolda as we continue on our mission to develop medicines for people living with rare diseases," Bradley Campbell, Amicus Therapeutics President and CEO.